Clinical trials: Flu
Influenza A Subtype H5N1 Infection
Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
The study is a prospective single site exploratory study to examine the impact of Food and Drug Administration (FDA) approved seasonal flu vaccine on the immune responses of H5N1 vaccine previously received with or without the…
- Trial name
- HIPCVAX-010S (NCT03701061)
- Testing
- Seasonal Influenza Vaccine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Emory University
Quality of Life, Injection Site Reaction
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
This study is a prospective, randomized clinical trial. During this study, participants will be randomly assigned to receive quadrivalent inactivated influenza vaccine (IIV4) and mRNA COVID-19 vaccine either simultaneously or…
- Conditions
- Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
- Trial name
- NCT05028361
- Testing
- mRNA COVID-19, IIV4
- Where
- 3 sites in United States
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Duke University
Moderate to Severe Asthma
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous [SC] every 4 weeks [Q4W]) on antibody responses…
- Trial name
- VECTOR (NCT05062759)
- Testing
- Tezepelumab
- Where
- 15 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
HIV, Cancer
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
This is an open label-study of Fluzone HD, a high-dose form of trivalent, inactivated influenza vaccine (TIV), vs. Fluzone, a standard-dose form of TIV.
- Trial name
- NCT01205581
- Testing
- Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- St. Jude Children's Research Hospital
Influenza, Human
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza and non-adjuvanted influenza control…
- Trial name
- NCT00644059
- Testing
- Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
- Where
- 101 sites in Finland, Germany and 1 more
- Volunteers
- 4,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Immune Response to Influenza Vaccine, Influenza A Virus Infection
Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
The purpose of this study is to assess the serologic and cell-mediated immune response to licensed live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children 5-17 years old.
- Conditions
- Immune Response to Influenza Vaccine, Influenza A Virus Infection, Influenza B Virus Infection
- Trial name
- NCT02250274
- Testing
- LAIV, IIV
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Marshfield Clinic Research Foundation
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.
- Trial name
- NCT00940108
- Testing
- CSL425
- Where
- 5 sites in Australia
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age
The purpose of this study is to evaluate the immunogenicity and safety of the new influenza vaccine GSK2282512A (FLU Q-QIV) and compare its activity to Sanofi Pasteur's Fluzone® (TIV) in children 6 to 35 months of age.
- Trial name
- NCT01974895
- Testing
- FluLaval® Quadrivalent, Fluzone®
- Where
- 12 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Influenza
TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations
The Advisory Committee on Immunization Practices (ACIP)recommends that the flu vaccine be administered annually to all children aged 6 months to 18 years as well as women who are pregnant during the influenza season.
- Trial name
- NCT01146912
- Testing
- Text Message, automated call
- Where
- United States
- Volunteers
- 30,537 people
- Sponsor
- Columbia University
Influenza
B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
In this exploratory study, investigators will be looking at immune response differences between age groups and between the two different vaccines given to identical twins and vaccine-naive young adults.
- Trial name
- NCT03020537
- Testing
- Fluzone
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
The primary objective of the study was to provide sera (collected from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to the Center for Biologics Evaluation and Research (CBER) for…
- Trial name
- GRC00097 (NCT04109222)
- Testing
- Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine…
- Trial name
- NCT02914275
- Testing
- Seqirus Quadrivalent Inactivated Influenza Vaccine, Comparator Quadrivalent Inactivated Influenza Vaccine
- Where
- 39 sites in United States
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza Infection
Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants
The purpose of this study is to evaluate the safety and immunogenicity of an intramuscular injection of TAK-850 in healthy pediatric Japanese participants.
- Trial name
- NCT02367885
- Testing
- TAK-850 0.5 mL injection, TAK-850 0.25 mL injection
- Where
- 2 sites in Japan
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to <1 year with influenza like symptoms
- Trial name
- NCT03653364
- Testing
- Baloxavir Marboxil
- Where
- 27 sites in United States, Bulgaria and 7 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Influenza, Human
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
This phase 3 clinical study is a randomized, observer-blind, comparator-controlled, multicenter study of QIVc versus a US-licensed comparator QIV in children 6 months through 47 months of age.
- Conditions
- Influenza, Human, Virus Diseases
- Trial name
- NCT04074928
- Testing
- QIVc, Comparator QIV
- Where
- 47 sites in United States
- Volunteers
- 2,414 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England
This pilot study, to be conducted in the 2017/2018 influenza season, is a safety surveillance study using passive surveillance enhanced with a reporting card system to report adverse events of interest (AEIs) after Flu…
- Trial name
- NCT03278067
- Testing
- Enhanced vaccine safety surveillance
- Where
- United Kingdom
- Volunteers
- 23,939 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
This study will be an open-label, multi-center, single arm study to evaluate the safety and efficacy of IV zanamivir 600mg twice daily for 5 days in hospitalized subjects with laboratory confirmed influenza infection.
- Trial name
- NCT01527110
- Testing
- Intravenous (IV) zanamivir
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Influenza Virus
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to <72 Months of Age.
- Trial name
- NCT01964989
- Testing
- Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
- Where
- 167 sites in United States, Canada and 9 more
- Volunteers
- 10,644 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine.
- Trial name
- NCT00944073
- Testing
- Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
- Where
- 9 sites in United States
- Volunteers
- 583 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)